Across TCGA pan-cancer cohorts, SVIL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SVIL data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SVIL mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SVIL expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where SVIL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	1.000	0.699	<.001	35	view →
HNSC	OS	Median	IV	0.590	0.826	.012	11	view →
LSCC	DFS	Median	III,IV	0.611	0.947	.023	7	view →
LUAD	DFS	Quartile	II,III,IV	0.368	0.799	.044	2	view →
GBM	OS	Median	All	0.278	0.469	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SVIL tumor-vs-normal RNA expression · all SVIL data types